Q2 2018

Filed Aug 8, 2018 · 10-Q · 39 days after period end · 0000886163-18-000113

Q2 2018 · 10-Q

Revenue

$90.04M

±0.0% vs Q2 2017

Net Income

$73.16M

±0.0% vs Q2 2017

EPS Diluted

$2.99

±0.0% vs Q2 2017

Operating Income$70,175,000+439.2%

Operating Cash Flow

Same quarter

Metric	Q2 2018	Q2 2017	Q2 2016	Q2 2015
Revenue	$90.04M	$90.04M	$19.52M	$18.42M
Net Income	$73.16M	$73.16M	-$6.17M	$23.56M
EPS Diluted	$2.99	$2.99	-$0.30	$1.11

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR